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Development of interfering RNA agents 
to inhibit SARS-associated coronavirus 
infection and replication
Key Messages
1. Small interfering RNAs (siRNAs) 
were designed to knock-down 
the four structural genes in severe 
acute respiratory syndrome–
associated coronavirus (SCoV). 
Antiviral effects were confirmed 
by reduction of viral cytopathic 
effects and reduction in viral 
genomic RNA. 
2. The siRNAs inhibited SCoV in 
a dose-dependent manner and 
had half-lives of approximately 
24 hours.
3. The siRNAs acted synergistically 
with each other at low doses 
to enhance inhibition of 
SCoV. Specific siRNAs acted 
synergistically with interferon-
α to massively (~100 000-
fold) inhibit SCoV replication, 
compared to controls.
4. Recombinant adenovirus–based 
vectors expressing short hairpin 
RNA molecules were developed 
that potently inhibited SCoV 
replication and virus production.
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Introduction
In 2003, severe acute respiratory syndrome (SARS) spread to over 30 countries, 
infected over 8400 individuals and killed 813 people around the world. A novel 
SARS-associated coronavirus (SCoV) was identified as the causative agent.1 It 
was likely that SCoV originated from wild animals and was later transmitted to 
humans as a SCoV-like viral pool, which was present in a large number of wild 
animals.2 This syndrome can be transmitted through the airway or nasal passage, 
urine, water and domestic pets.3 A vaccination or specific anti-SARS agent has 
not yet been developed.
 The SCoV is a large, enveloped, positive-stranded RNA virus and its genome 
is composed of 30 000 nucleotides. The organisation of the genome is typical 
of the coronaviruses, following the characteristic gene order 5’-replicase (rep), 
spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3’. The rep gene 
products are translated from genomic RNA and play key roles in viral replication 
and gene transcription, whereas the structural proteins are essential for virus 
package and infection. They are translated from subgenomic mRNAs, which are 
synthesised through a discontinuous transcription process.1 
 Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) are 
potent agents for silencing gene expression, viral infection and replication in a 
sequence-specific manner. Replicase has long been the favourite target for antiviral 
drug development. We were the first group to demonstrate that siRNAs targeting 
the rep gene potently inhibited SCoV infection and replication.4 However, recent 
studies revealed that viruses could easily escape siRNA targeting through fast 
mutagenesis.5 Therefore, identification of multiple effective siRNAs targeting 
different sites or functional genes of SCoV could be an alternative treatment for 
any possible recurrence of the SARS epidemic. Our objectives were: (1) to design 
siRNAs to knock-down the four structural genes (S, E, M, N); (2) to test their 
antiviral effects; (3) to investigate the half-lives of siRNAs and dose responses; 
(4) to test the potential for combined synergistic antiviral effects of different 
siRNAs; (5) to test the potential synergistic effects of siRNA with interferon 
(IFN)-α; and (6) to develop a deliverable recombinant adenovirus system (rAd-
shRNA).
Methods
This study was conducted from March 2005 to February 2007.
siRNA design, synthesis, and screening 
We designed and synthesised three siRNAs for each targeting gene. We selected 
the most effective siRNAs targeting each gene by cytopathic effect (CPE) assay. 
They were CACUGAUUCCGUUCGAGAUC (SARSi-S), CGUUUCGGAA 
GAAACAGGUAC (SARSi-E), CAAGCCUCUUCUCGCUCCUC 
(SARSi-N), UGCUUGCUGCUGUCUACAG (SARSi-M1), and 
GUGGCUUAGCUACUUCGUUG (SARSi-M2). The sequences 
corresponded to nucleotides 23150-23169, 26113-26133, 28648-28667, 
26576-26594, and 26652-26671 of GZ50 stain (GenBank accession number 
AY304495), respectively. SARSi-R or SRASi-4, the most potent siRNA targeting 
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the rep gene (GCACUUGUCUACCUUGAUG)5 was used 
as a positive control. 
Cell culture, transfection and SCoV infection
Foetal rhesus kidney (FRhk-4) cells were cultured and 
maintained in minimum essential medium (MEM) with 
10% foetal bovine serum (FBS) [Invitrogen, CA, US]. 
Around 5000 cells were set in each well of a 96-well dish 
for viral infection and replication assay. The cells were 
transfected either without (negative control) or with siRNA 
at a standard concentration (200 nM) using OligoFectamine 
(Invitrogen, CA, US), in accordance with the manufacturer’s 
instructions. Six hours after transfection, the culture 
medium was removed and the cells were washed twice 
with phosphate buffered saline before SCoV infection. 
One hundred microlitres of SARS-associated coronavirus 
(GZ50) diluted in MEM with 1% FBS was added to the 
transfected cells (multiplicity of infection 0.05). The 
CPEs were observed and recorded under phase-contrast 
microscopy 36 hours post-infection. 
Construction of Adv-shRNA vectors
We synthesised nucleotide oligos encoding effective 
siRNAs (SARSi-2, SARSi-3, SARSi-4, SARSi-S and 
SARSi-M1). A loop TTCG sequence was added between 
the sense and antisense strand and a transcriptional 
termination sequence TTTTT was added after the 
antisense sequence. After annealing, the oligos were 
cloned downstream of a human U6 promoter (pAVU6+27). 
Then shRNA expression cassettes were subcloned into 
pAdeno-X (ClonTech, CA, US) to generate pAdeno-X-
SARSi serial constructs. We packaged Adeno-X-SARSi 
viral vectors in HEK 293 Cells and purified the vectors 
using an adenovirus purification kit (ClonTech, CA, US) 
according to the manufacturer’s instructions. FRhk-4 
cells were transduced at a multiplicity of infection (MOI) 
10:1 one hour before SCoV challenge. 
Dual treatment with siRNA and IFN-α
To investigate the synergistic effects of siRNAs and IFN-
α, siRNAs were first transfected into FRhk-4 cells. Four 
hours after transfection, the cells were treated with IFN-α at 
different concentrations. The cells were infected with SCoV 
1 hour after incubation with IFN-α. The virus titre and RNA 
level of SCoV were measured as described above.
Quantitative reverse transcription–polymerase chain 
reaction
We used real time (RT) reverse transcription–polymerase 
chain reaction (PCR) to quantify the intracellular viral RNA 
level as described previously.5 
Titration of viral titres
The conditioned medium from infected cells was subjected 
to 10-fold serial dilutions in MEM with 1% FBS and used 
for infecting cells according to the standard protocol. 
Briefly, cells were set in 96-well dishes 16 hours before 
infection. Seventy-two hours post-infection, CPE was 
observed and recorded under phase-contrast microscopy, 
and the infectious viral titre was calculated.
Results
Design and synthesis of siRNAs
We designed and synthesised 12 siRNAs (3 for each gene) 
to target S, E, M, and N genes. We tested and selected the 
most effective siRNAs by CPE assay. 
Determining antiviral effects of siRNAs 
Protection of cytopathic effects 
FRhk-4 cells were set in 96-well dishes and transfected 
with or without siRNAs. The cells were infected with SCoV 
6 hours after transfection, and CPE was monitored under 
phase-contrast microscopy. Cytopathic effects appeared 
when cells were transfected without or with GL2i (control 
siRNA targeting luciferase mRNA) and infected with SCoV. 
As effective siRNAs targeting replicase, cells transfected 
with effective siRNAs targeting structural genes (SARSi-
S, SARSi-E, SARSi-M1, SARSi-M2 and SARSi-N) were 
protected from CPE. 
Reduction of viral genomic RNA copies 
The antiviral effects of individual effective siRNA were 
further characterised by determination of the copy number 
of intracellular viral genomic RNA using RT-PCR assays. 
The intracellular viral RNA level was reduced by 67.3 to 
83.3% (83.3% by SARSi-S, 74.0% by SARSi-E, 77.5% by 
SARSi-M1, 81.7% by SARSi-M2, and 67.3% by SARSi-N) 
compared with the GL2i control at a standard concentration 
(200 nM). These results indicated that siRNAs potently 
inhibited SCoV RNA replication. 
The half-lives of siRNAs and dose response against 
viral replication
Kinetics of intracellular viral genomic RNA
The half-lives of siRNAs were investigated by determining 
viral kinetics of the cells being treated with siRNAs. The 
siRNA was transfected into FRhk-4 cells 6 hours before 
infection with SCoV. Quantitative RT-PCR experiments 
were carried out to determine SCoV genomic RNA copies 
in the infected cells at different time points (1, 6, 12, 18 
and 24 hours post-infection). As the SCoV RNA level was 
markedly inhibited during the first 18 hours and then began 
to increase fast, the half-lives of siRNAs in FRhk-4 cells 
were about 24 hours in FRhk-4 cells. 
Inhibition of viral reproduction in a dose-dependent 
manner
At doses of 1, 5, 20, 80, or 200 nM of SARSi-R in the 
transfection mixtures, the viral titre was reduced by 4.8, 
16.6, 22.2, 25.4, and 33.4 folds respectively. Similarly, viral 
titres were reduced 3.1, 5.3, 10.5, 15.7 and 23.4 folds at 
doses of 1, 5, 20, 80, and 200 nM of SARSi-S, respectively. 
Similar results were obtained from SARSi-E, SARSi-M1 
and SARSi-M2. SARSi-N showed lower relative activities 
at different dosages. 
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Synergistic inhibitory effects of siRNAs 
combinations at low dose
There was a saturated siRNA concentration, and 
combinations of siRNAs against the same gene did not 
increase the antiviral activities. If synergistic antiviral 
effects would be achieved with combined siRNAs targeting 
different genes at lower doses, it would offer an opportunity 
to develop cost-effective and specific agents to combat 
any SARS outbreak and drug resistance in the future. The 
concentration was decreased from 200 nM to 10 nM, the 
viral titre was reduced from about 30 folds to 5 folds by 
SASRi-R, 8 folds by SARSi-E, 2 folds by SARSi-S, -M1 
or -M2, respectively. However, it was intriguing that anti-
SCoV effects could be restored with two siRNAs targeting 
different genes at this dose. Compared with the control, the 
viral titres were reduced over 50-fold for SARSi-R/-S and 
SARSi-S/-E combinations, about 18-fold for SARSi-R/-
M1 and SARSi-S/-M2 combinations, and over 30-fold for 
SARSi-R4/-E combinations, respectively. 
Synergistic effect of siRNA in combination with 
IFN-α 
The viral titres were 106.5 particles/mL in the media of 
cells transfected with or without mock siRNA. When the 
cells were treated with IFN-α alone, the viral titres were 
reduced about 100 times (from 106.5 to 104.5 particles/mL). 
In contrast, the viral titres were reduced over 100 times 
by SARSi-M1 alone (from 106.5 to 104.25 particles/mL) and 
nearly 1000 times by SARSi-R alone (from 106.5 to 102.75 
particles/mL). However, the viral titres were reduced 100 000 
times when IFNα was combined with either SARSi-R or 
SARSi-M1. In conclusion, siRNAs exhibited synergistic 
antiviral effects with IFN-α. The viral RNA levels were 
significantly reduced and the viral titres were reduced 
more than 100 times the levels with either siRNA or IFN-α 
alone. This was particularly important, as it not only greatly 
enhanced antiviral effects, but also reduced costs.
Inhibition of SCoV by recombinant Adv-shRNA 
vectors
Adv-shRNAs potently inhibited SCoV replication and virus 
production. The intracellular viral RNA was reduced more than 
95% (adv-SARSi-R) at MOI 10. The viral titres were reduced 
over 100-fold at low MOI (MOI=1), and further reduced over 
1000-fold (but less than 10 000-fold) at higher MOI (MOI=10). 
Taken together, SCoV was potently inhibited by adv-shRNA 
vectors to at least a similar degree as the original siRNAs. 
Discussion
We hypothesised that RNAi targeting structural genes 
could also exhibit antiviral effects, which might show 
synergistic effects when combined with each other or with 
the effective siRNA targeting replicase gene.5 This would 
reduce drug resistance generated via virus mutations.4 In 
this study, we developed siRNAs targeting S/E/M structural 
genes, which inhibited viral RNA accumulation in host 
cells with lower efficiency while exhibited almost the same 
inhibitory activities for viral reproductions. There may be 
several reasons for this phenomenon. Firstly, viral genomic 
RNA will be immediately translated into viral proteins 
and undergo a fast RNA replication phase when it enters 
cells. Replicase is encoded by viral genomic RNA and is 
directly responsible for viral RNA synthesis. Therefore, 
siRNA targeting the replicase region will directly reduce 
replicase. Secondly, the 3’-region of viral genomic RNA 
encodes for several subgenomic mRNAs. The subgenomic 
mRNAs are abundant in the host cells, which may reduce 
target efficiency or prolong the siRNA-induced cleavage 
of viral genomic RNA. Finally, active transcription and/
or translation in the 3’-region of viral genomic RNA may 
block siRNA target sites. However, the structural gene 
products directly contribute to viral package and infectious 
activities. The accumulated infectious viruses rely on both 
replication and the correct, effective package. Therefore, 
SARSi-S/-E/-M1/-M2 could display a similar degree of 
inhibitory activities in the production of infectious virions 
as SARSi-R at saturation in the media. 
 
 Kinetics studies showed the intracellular viral RNA 
accumulation was potently inhibited in the first 18 hours, 
indicating that the transfected siRNAs in FRhk-4 cells 
had short half-lives (about 24 hours). Therefore, sustained 
shRNA expression vectors—Adv-shRNA vectors—were 
developed. These vectors showed similar antiviral effects 
as the original siRNAs, which would offer an alternative 
for anti-SARS therapy.
 Various combinations of siRNAs targeting different 
genes produced synergistic anti-SCoV effects. A single 
siRNA at a low concentration (10 nM) significantly reduced 
antiviral activity while combination of two siRNAs targeting 
different functional genes restored their antiviral activities 
at saturated concentrations, suggesting that combinations 
of effective siRNAs could be used in clinical applications 
with reduced toxicity and at a lower cost. More importantly, 
the effective siRNAs tested in this study showed synergistic 
antiviral effects with IFN-α, which might provide a powerful 
anti-SARS tool in the future.
 In conclusion, we developed multiple effective siRNAs 
targeting different genes of SCoV, including replicase, 
spike, envelope, membrane and nucleocapsid, which could 
potently inhibit SCoV replication in a dose-dependent 
manner. The half-lives of these siRNAs were about 24 hours 
in FRhk-4 cells and exhibited synergistic antiviral effects in 
combination even at very low doses. After conversion into 
shRNA by using adenovirual vectors, the respective shRNA 
exhibited similar antiviral effects as the original siRNA. 
These effective siRNAs also showed synergistic antiviral 
effects with IFN-α, which might provide a powerful anti-
SARS tool in the future.
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